Benjamin Young

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11099030/publications.pdf

Version: 2024-02-01

49 papers	2,810 citations	218677 26 h-index	233421 45 g-index
51 all docs	51 docs citations	51 times ranked	3264 citing authors

#	Article	IF	Citations
1	Treatment challenges and health conditions among people living with HIV with or without substance use disorder in the Russian Federation. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 1276-1281.	1.2	5
2	Drug-drug interactions with antiretroviral therapy among people living with HIV in Asia and other regions: risk factors and impact on indicators of health-related quality of life. Population Medicine, 2022, 4, .	0.8	0
3	Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIV. AIDS and Behavior, 2021, 25, 1384-1395.	2.7	28
4	Undetectable equals untransmittable (U = U): awareness and associations with health outcomes among people living with HIV in 25 countries. Sexually Transmitted Infections, 2021, 97, 18-26.	1.9	87
5	Physical, Emotional, and Psychosocial Challenges Associated with Daily Dosing of HIV Medications and Their Impact on Indicators of Quality of Life: Findings from the Positive Perspectives Study. AIDS and Behavior, 2021, 25, 961-972.	2.7	33
6	Regional differences in perceived treatments needs and priorities in relation to antiretroviral therapy among people living with HIV in 25 countries. Preventive Medicine, 2021, 142, 106372.	3.4	7
7	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. Nature Communications, 2021, 12, 1660.	12.8	132
8	Lessons learned from SARS-CoV-2 measurements in wastewater. Science of the Total Environment, 2021, 798, 149177.	8.0	36
9	Quantifying unmet treatment needs among people living with HIV in Australia and other countries. Population Medicine, 2021, 3, 1-14.	0.8	0
10	Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries. Preventive Medicine, 2020, 139, 106182.	3.4	31
11	The Complicated Evolutionary Diversification of the Mpeg-1/Perforin-2 Family in Cnidarians. Frontiers in Immunology, 2020, 11, 1690.	4.8	9
12	Relationship Between Polypharmacy and Quality of Life Among People in 24 Countries Living With HIV. Preventing Chronic Disease, 2020, 17, E22.	3.4	33
13	Treatment aspirations and attitudes towards innovative medications among people living with HIV in 25 countries. Population Medicine, 2020, 2, .	0.8	15
14	Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. HIV/AIDS - Research and Palliative Care, 2017, Volume 9, 51-61.	0.8	4
15	Low Bone Mineral Density and Risk of Incident Fracture in HIV-Infected Adults. Antiviral Therapy, 2016, 21, 45-54.	1.0	42
16	Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?. Current Opinion in HIV and AIDS, 2016, 11, 301-305.	3.8	24
17	Estimated glomerular filtration rates through 144â€Šweeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clinical Trials, 2015, 16, 125-129.	2.0	3
18	The HIV care continuum in Latin America: challenges and opportunities. Lancet Infectious Diseases, The, 2015, 15, 833-839.	9.1	59

#	Article	IF	Citations
19	Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999â€“2011. Journal of Antimicrobial Chemotherapy, 2015, 70, 2337-2346.	3.0	16
20	The HIV care cascade through time. Lancet Infectious Diseases, The, 2014, 14, 5-6.	9.1	58
21	Bones, Fractures, Antiretroviral Therapy and HIV. Current Infectious Disease Reports, 2014, 16, 393.	3.0	18
22	Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naive HIV-Infected Patients Treated for 144 Weeks with Abacavir/Lamivudine/Atazanavir with or without Ritonavir in ARIES. AIDS Research and Human Retroviruses, 2013, 29, 350-358.	1.1	20
23	Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study. Journal of Infectious Diseases, 2013, 207, 740-748.	4.0	271
24	Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999â€“2008. AIDS Research and Treatment, 2012, 2012, 1-10.	0.7	10
25	ARIES 144 Week Results: Durable Virologic Suppression in HIV-Infected Patients Simplified to Unboosted Atazanavir/Abacavir/Lamivudine. HIV Clinical Trials, 2012, 13, 233-244.	2.0	27
26	Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infectious Diseases, The, 2012, 12, 111-118.	9.1	260
27	Transmission of Integrase Strand-Transfer Inhibitor Multidrug-Resistant HIV-1: Case Report and Response to Raltegravir-Containing Antiretroviral Therapy. Antiviral Therapy, 2011, 16, 253-256.	1.0	63
28	Increased Rates of Bone Fracture Among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared With the US General Population, 2000-2006. Clinical Infectious Diseases, 2011, 52, 1061-1068.	5.8	228
29	A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-NaÃ¯ve HIV-1â€“Infected Patients: 48-Week Results of the SHIELD Trial. HIV Clinical Trials, 2010, 11, 260-269.	2.0	20
30	Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. Aids, 2010, 24, 2019-2027.	2.2	60
31	Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients. HIV Clinical Trials, 2010, 11, 69-79.	2.0	25
32	Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet, The, 2010, 375, 396-407.	13.7	276
33	Acute Onset Insomnia Associated with the Initiation of Raltegravir: A Report of Two Cases and Literature Review. AIDS Patient Care and STDs, 2009, 23, 689-690.	2.5	21
34	Renal Function in Patients with Preexisting Renal Disease Receiving Tenofovir-Containing Highly Active Antiretroviral Therapy in the HIV Outpatient Study. AIDS Patient Care and STDs, 2009, 23, 589-592.	2.5	28
35	Kidney Disease in Patients with HIV Infection and AIDS. Clinical Infectious Diseases, 2008, 47, 1449-1457.	5.8	95
36	First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. Aids, 2008, 22, 1673-1675.	2.2	81

#	Article	IF	Citations
37	Renal Function in Tenofovir-Exposed and Tenofovir-Unexposed Patients Receiving Highly Active Antiretroviral Therapy in the HIV Outpatient Study. Journal of the International Association of Providers of AIDS Care, 2007, 6, 178-187.	1.2	43
38	Short-Term Safety and Tolerability of Didanosine Combined with High- versus Low-Dose Tenofovir Disproxil Fumarate in Ambulatory HIV-1â€“Infected Persons. AIDS Patient Care and STDs, 2006, 20, 238-244.	2.5	11
39	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet, The, 2006, 368, 476-482.	13.7	345
40	Renal Function in Patients Receiving Tenofovir With Ritonavir/Lopinavir or Ritonavir/Atazanavir in the HIV Outpatient Study (HOPS) Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 626-628.	2.1	38
41	PA update: DHHS guidelines for the treatment of HIV infection. JAAPA: Official Journal of the American Academy of Physician Assistants, 2006, Suppl, 3-13.	0.3	0
42	Review:Mixing New Cocktails: Drug Interactions in Antiretroviral Regimens. AIDS Patient Care and STDs, 2005, 19, 286-297.	2.5	32
43	The Role of Nucleoside and Nucleotide Reverse Transcriptase Inhibitor Backbones in Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, S13-S20.	2.1	3
44	Open-Label Study of a Twice-Daily Indinavir 800-mg/Ritonavir 100-mg Regimen in Protease Inhibitorâ€“Naive HIV-Infected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2002, 31, 478-482.	2.1	27
45	Improving the fit of bivariate smoothing splines when estimating longitudinal immunological and virological markers in HIV patients with individual antiretroviral treatment strategies. Statistics in Medicine, 2001, 20, 2489-2504.	1.6	3
46	Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment with Zidovudineâ€Lamivudineâ€Ritonavir: Genotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from AIDS Clinical Trials Group Protocol 315. Journal of Infectious Diseases, 2000, 181, 491-497.	4.0	41
47	Reply. Journal of Infectious Diseases, 1999, 180, 570-571.	4.0	0
48	Resistance Mutations in Protease and Reverse Transcriptase Genes of Human Immunodeficiency Virus Type 1 Isolates from Patients with Combination Antiretroviral Therapy Failure. Journal of Infectious Diseases, 1998, 178, 1497-1501.	4.0	56
49	Specificity for 3â€²,5â€²-linked substrates in RNA-catalyzed RNA polymerization. Journal of Molecular Evolution, 1989, 29, 480-485.	1.8	8